Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01681264 · ClinicalTrials.gov registry record · Phase 4
Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 137
- Enrollment target
NCT01681264: Clinical Trial Phase 4 study, sponsored by Massachusetts General Hospital.
NCT01681264 is a Phase 4 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 137 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01681264, a Phase 4 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 137 participants
- Enrollment target
Study Summary
Dual medication (guanfacine and morphine) as a standard treatment for chronic pain.
Primary Outcome
Change in numeric pain score (from 0-10: 0 being no pain; 10 being worst pain) was used to measure changes in pain.
Interventions
- DRUG Placebo
- DRUG Morphine
- DRUG Guanfacine 1mg
- DRUG Guanfacine 2mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2014-09 |
| Est. Completion | 2023-12 |
| Phase | Phase 4 |
Why NCT01681264 stopped before completion
NCT01681264 is an interventional study that assigns participants to a tested intervention. The registered 137 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01681264 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01681264 about?
NCT01681264 is a clinical study titled "Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance". Dual medication (guanfacine and morphine) as a standard treatment for chronic pain.
What is the current status of trial NCT01681264?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 137 participants. The study started on 2014-09. Estimated completion is 2023-12.
What interventions are being tested in trial NCT01681264?
The interventions under investigation include: Placebo (DRUG), Morphine (DRUG), Guanfacine 1mg (DRUG), Guanfacine 2mg (DRUG).
Who is sponsoring clinical trial NCT01681264?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01681264's enrollment target sits among peer trials
137 594th of 2000 higher than 1,405 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05091424 · 137 participants · Phase 1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- NCT05655182 · 137 participants · Phase 1
A Study of BLB-201 RSV Vaccine in Infants and Children
- NCT06571669 · 137 participants · NA
BOOM-IBD2 Pivotal Clinical Trial
- NCT06644768 · 137 participants · Phase 1
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia